In summary, we found that the NLR, CRP/Alb ratio and PLR were all potential markers for the survival of Xp11.2 tRCC; thus, they could be considered for clinical decision-making. The gene discussed is CRP; the disease is renal cell carcinoma associated with Xp11.2 translocations/TFE3 gene fusions.